about
iTRAQ quantitative analysis of Francisella tularensis ssp. holarctica live vaccine strain and Francisella tularensis ssp. tularensis SCHU S4 response to different temperatures and stationary phases of growth.Characterization of tetratricopeptide repeat-like proteins in Francisella tularensis and identification of a novel locus required for virulenceRole of ABC and Solute Carrier Transporters in the Placental Transport of Lamivudine.Tetratricopeptide repeat motifs in the world of bacterial pathogens: role in virulence mechanisms.Multidrug and toxin extrusion proteins (MATE/SLC47); role in pharmacokinetics.Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta.Azole antimycotics differentially affect rifampicin-induced pregnane X receptor-mediated CYP3A4 gene expression.Current antiviral drugs and their analysis in biological materials-Part I: Antivirals against respiratory and herpes viruses.Examination of Glucocorticoid receptor alpha-mediated transcriptional regulation of P-glycoprotein, CYP3A4, and CYP2C9 genes in placental trophoblast cell lines.Long-term administration of tenofovir or emtricitabine to pregnant rats; effect on Abcb1a, Abcb1b and Abcg2 expression in the placenta and in maternal and fetal organs.Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways.Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters.Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents.Current antiviral drugs and their analysis in biological materials - Part II: Antivirals against hepatitis and HIV viruses.MDR1 and BCRP Transporter-Mediated Drug-Drug Interaction between Rilpivirine and Abacavir and Effect on Intestinal Absorption.Role of nucleoside transporters in transplacental pharmacokinetics of nucleoside reverse transcriptase inhibitors zidovudine and emtricitabine.Role of ABCB1, ABCG2, ABCC2 and ABCC5 transporters in placental passage of zidovudine.Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir.Organic Cation Transporter 3 (OCT3/SLC22A3) and Multidrug and Toxin Extrusion 1 (MATE1/SLC47A1) Transporter in the Placenta and Fetal Tissues: Expression Profile and Fetus Protective Role at Different Stages of Gestation1Expression of Concentrative Nucleoside Transporters ( SLC28A) in the Human Placenta: Effects of Gestation Age and Prototype Differentiation-Affecting Agents.Equilibrative Nucleoside Transporter 1 (ENT1, ) Facilitates Transfer of the Antiretroviral Drug Abacavir across the PlacentaDeletion of IglH in virulent Francisella tularensis subsp. holarctica FSC200 strain results in attenuation and provides protection against the challenge with the parental strainInteractions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in ratsS-(4-Nitrobenzyl)-6-thioinosine (NBMPR) is Not a Selective Inhibitor of Equilibrative Nucleoside Transporters but Also Blocks Efflux Activity of Breast Cancer Resistance ProteinAre ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?Transport of ribavirin across the rat and human placental barrier: Roles of nucleoside and ATP-binding cassette drug efflux transportersAnti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal SlicesDually directional glycosylated phthalocyanines as extracellular red-emitting fluorescent probes
P50
Q33439012-02490636-E5BE-4812-9BDE-7DBA573686E3Q34595801-7B074DF7-9209-4C3C-9F3C-5DD2A38AFDD1Q37203806-0FF5D683-C8A5-4053-B899-2B0D59F148B9Q38069528-88951E00-AD5C-4457-AA30-D4E9190CC1B0Q38119818-70E52161-6F8B-481D-A2B2-F314AD4B2B02Q39035326-F76B31C6-CD7D-479F-ACF6-E493101442CAQ40052938-B94D4EB3-A0FA-49F1-9323-E2461418391FQ40102940-7FA59277-0684-4330-BCCC-6AFA1B4B657AQ40119245-EC466EF3-1F8B-40AB-B190-D4E614D39292Q40148984-0CB3C207-8769-471B-A75E-C5F6C19FFFE0Q40152929-61CEDCFC-C03B-4253-A228-B29651DE3D7DQ42491474-E0D66542-52DF-47E3-A1D4-1B798C67DB34Q46984881-45780403-5A28-433C-947D-96813FBF01DFQ47612729-1BF56891-39E3-45F7-A90E-964D5512281BQ48145638-4C243564-842D-4E7C-8D31-B40E318AE373Q50060533-DEA7ACBD-8347-4193-851E-CBE945F0236DQ53816970-2BCD3359-964D-4CFF-ADC1-0A8A40EF21DDQ53832622-44C71A56-D50F-4074-A24E-9B2AB121DC1FQ54601113-2019C90D-9848-425E-B48D-A973696399F4Q54978677-053B3167-7850-4F8D-9EF2-7A8AEE340525Q59354776-B36DF7A9-ABCE-4165-8E3E-B124232ADA3DQ84963610-B6F11642-A32E-40DE-8D9F-1CC92577A012Q88957629-0951C855-D9D7-4F14-AFEF-FF39C4E25081Q89838827-D8A1FC3B-CD6D-4623-AF13-4D9C800BB0BDQ90945174-5547D014-8575-410B-8430-2B7F0495AADEQ91332936-4FAACD3C-F000-4E3E-833C-9A92A628E2DEQ93085314-8B996ABA-F2C5-4DF8-B36F-223B3EA22FCFQ96432580-DA31DBDA-8A0A-475F-9737-4D63127E6CB3
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Lukas Cerveny
@en
Lukas Cerveny
@nl
type
label
Lukas Cerveny
@en
Lukas Cerveny
@nl
prefLabel
Lukas Cerveny
@en
Lukas Cerveny
@nl
P31
P496
0000-0002-1313-306X